EXECUTIVE SUMMARY

Introduction
Strategic scoping and focus
Key findings
Key growth drivers and resistors facing healthcare payers and pharma
Biosimilars overview
Related reports
Upcoming related reports

2. GLOBAL BIOSIMILAR MARKET SIZE
Biosimilar definitions
Biosimilar sales during 2008–10
Biologic sales exposed to potential biosimilar competition during 2011–15
Profitability of biosimilars versus branded biologics and generics

3. DRIVERS AND RESISTORS TO BIOSIMILAR UPTAKE
Drivers and resistors to biosimilar uptake in the developed markets
Drivers of biosimilar uptake in developed markets
Neutral factors impacting biosimilar uptake in developed markets
Resistors to biosimilar uptake in developed markets
Drivers and resistors to biosimilar uptake in Brazil, Russia, India, and China
Drivers of biosimilar uptake in emerging markets
Resistors impacting biosimilar uptake in emerging markets

4. BIOSIMILAR MARKET ACCESS
Key factors in determining the success of biosimilar market access
Biosimilar development timeline
Biosimilar development costs
Pros and cons of developing and manufacturing biosimilars in developing markets
Biosimilar approval pathways
Biosimilar producers face a challenging patent environment
Biosimilar pricing in developed markets
Partnerships help drive growth of the biosimilars industry

5. KEY BIOSIMILAR PLAYERS
Key biosimilar players in the developed and emerging markets
Key biosimilar players

6. BIOSIMILARS BY GEOGRAPHIC MARKET
Biosimilar launches
US biosimilars market
Biosimilars in the five major EU markets
Japanese biosimilars market
Australian biosimilars market

7. BIOSIMILAR UPTAKE
Uptake of biosimilar somatropin, filgrastim and epoetin
Biosimilar somatropin
Biosimilar filgrastim
Biosimilar epoetin

8. OPPORTUNITIES FOR THE BIOSIMILAR INDUSTRY
Branded biologic patent expiries present opportunities for the biosimilar industry
Biologic patent expiries in the US
Biologic patent expiries in the five major EU markets
Biologic patent expiries in Japan
Biosimilar MAbs and second-generation biosimilars offer the greatest commercial potential

9. BIBLIOGRAPHY
Publications and online articles

APPENDIX
Exchange rates used in this report

TABLES

Table: Comparison of operating margins for branded biologics, branded prescription pharma, and generics companies, 2009
Table: Estimated savings anticipated to be gained through the use of biosimilar drugs
Table: Estimated costs associated with the development and registration of biosimilar drugs in the EU, Japan, US, Brazil, Russia, India, and China ($m), 2010
Table: Biosimilar approval pathways in key markets
Table: Biosimilar discount difference versus reference brand in key markets (%), 2010
Table: Pharma companies engaged in biosimilars-related deals, 2009–11
Table: Leading global biosimilars companies in the year to March 2010
Table: Sandoz/Hexal’s biosimilar product portfolio, 2010
Table: Teva’s biosimilar product portfolio, 2010
Table: Medice’s biosimilar product portfolio, 2010
Table: Stada’s biosimilar product portfolio, 2010
Table: Hospira’s biosimilar product portfolio, 2010
Table: US sales of Tev-Tropin and Omnitrope, 2009
Table: Biosimilars approved and rejected in the five major EU markets by the European Medicines Agency, 2011
Table: Biosimilars approved in Japan, 2010
Table: Biosimilars approved in Australia, 2010
Table: Global sales of biosimilar somatropin in the twelve months to March 2010
Table: Global sales of biosimilar filgrastim in the twelve months to March 2010
Table: Global sales of biosimilar epoetin in the twelve months to March 2010
Table: US sales (based on 2009 sales) of biologics both expired and expected to come off-patent, 2010–14
Table: Five major EU market sales (based on 2009 sales data) of biologics both expired and expected to come off-patent, 2010–14
Table: Japan sales (based on 2009 sales data) of biologics both expired and come off-patent, 2010–14
Table: Currency exchange rates, 2010

FIGURES

Figure: Key growth drivers and resistors facing healthcare payers and pharma
Figure: Comparison of global biosimilar market size by molecule, 2008–10
Figure: Value of branded biologics facing patent expiry, 2008–15
Figure: Developed markets – key factors influencing the biosimilar industry
Figure: The hospital versus retail divide for biosimilars
Figure: Emerging markets – key factors influencing the biosimilar industry
Figure: Biosimilar development timeline in the EU
Figure: Issues developing biosimilars in emerging markets for approval in developed markets
Figure: Biosimilar approval pathway in the US, EU, Japan, and Australia
Figure: Value of branded biologics facing patent expiry, 2008–15
Figure: Drivers and resistors to biosimilar monoclonal antibody market entry, 2010